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Abstract: Secukinumab is a human monoclonal antibody targeting IL-17A that has been 
approved for three indications: moderate-to-severe plaque psoriasis, psoriatic arthritis, and anky-
losing spondylitis. In Phase III clinical trials for each of these three indications, secukinumab 
has proven to be both highly efficacious and well-tolerated. However, several biologic medica-
tions are currently approved for the treatment of moderate-to-severe plaque psoriasis, and many 
demonstrate excellent efficacy and safety. Due to this wide selection, it is often unclear how to 
choose biologics for specific patients. Important considerations in biologic selection include 
clinical efficacy, safety, cost, convenience, onset of action, and management of comorbid dis-
ease. This article aims to outline the key considerations in patient selection for the treatment of 
plaque psoriasis with secukinumab.
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Introduction
Psoriasis vulgaris is associated with significant comorbidity including depression,1–3 
increased risk of cardiovascular events,4,5 diminished quality of life,6 as well as overall 
increased mortality.7 Furthermore, up to 40% of psoriasis patients have or will develop 
comorbid psoriatic arthritis in their lifetime.8 Effective treatment of this chronic, 
immune-mediated systemic inflammatory disease is necessary to improve quality of 
life and possibly decrease the risk of comorbid disease in psoriasis patients.9–11
Biologic medications currently approved for the treatment of moderate-to-severe 
plaque psoriasis include TNF-α inhibitors (adalimumab, etanercept, infliximab), IL-17 
pathway inhibitors (ixekizumab, brodalumab, secukinumab), IL-12/IL-23 inhibitors 
(ustekinumab), and IL-23 inhibitors (guselkumab, tildrakizumab). Each medication 
has its own unique efficacy and safety profile. Dermatologists are fortunate to now 
have so many options available in the therapeutic armamentarium for moderate-to-
severe psoriasis patients, but it can be difficult to select specific biologics for individual 
patients. This article outlines key considerations in patient selection for the treatment 
of plaque psoriasis with secukinumab.
Practical considerations
Secukinumab (Cosentyx®, Novartis Pharmaceuticals Corporation, East Hanover, NJ, 
USA) is a recombinant human monoclonal IgG1 antibody that specifically binds to IL-
17A that has been approved for the treatment of adult patients with moderate-to-severe 
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plaque psoriasis, active psoriatic arthritis, or active ankylosing 
spondylitis.12
The recommended dosing for secukinumab differs for 
psoriasis as compared to psoriatic arthritis and ankylos-
ing spondylitis. Recommended dosing for plaque psoriasis 
patients is 300 mg administered subcutaneously at weeks 0, 
1, 2, 3, and 4 (loading dose), and every 4 weeks thereafter 
(maintenance).12 However, a lower dosage of 150 mg may 
also be used to improve tolerability. Patients with psoriatic 
arthritis or ankylosing spondylitis may use secukinumab 
with or without a loading dose. With a loading dose, 150 mg 
secukinumab is administered at weeks 0, 1, 2, 3, and 4 
(loading dose), and every 4 weeks thereafter (maintenance). 
Without a loading dose, 150 mg secukinumab is administered 
every 4 weeks. If patients continue to have active psoriatic 
arthritis, they may benefit from increasing the dose to 300 mg. 
Patients with both psoriatic arthritis and moderate-to-severe 
psoriasis are advised to use the dosing recommendations for 
plaque psoriasis.
Secukinumab is supplied as single-use 1 mL autoin-
jector pens and 1 mL prefilled syringes with a 27-gauge 
fixed ½-inch needle, each containing a 150 mg dose of the 
medication. Secukinumab can also be reconstituted from a 
lyophilized powder by a health care professional, with each 
vial containing 150 mg of the medication.
Secukinumab is contraindicated in patients with a hyper-
sensitivity reaction to secukinumab or to any of its excipi-
ents. It is recommended to evaluate patients for tuberculosis 
infection prior to initiating treatment with secukinumab. 
Secukinumab should be avoided in patients with preexist-
ing inflammatory bowel disease (IBD). Secukinumab may 
increase the risk for infection, and live vaccines should not 
be given to patients treated with secukinumab.
Efficacy in plaque psoriasis
Two pivotal randomized, controlled, double-blind Phase III 
trials evaluated the efficacy of secukinumab in patients with 
moderate-to-severe plaque psoriasis: ERASURE and FIX-
TURE.13 In all Phase III clinical trials for secukinumab for 
moderate-to-severe plaque psoriasis, patients in the treatment 
arm were dosed with 300 mg secukinumab administered once 
weekly for 5 weeks, then every 4 weeks thereafter (Table 1).
Secukinumab was compared with placebo in ERASURE 
and placebo or etanercept in FIXTURE.13 The coprimary 
efficacy endpoints in both studies were the proportion of 
patients treated with secukinumab who achieved ≥75% 
reduction in Psoriasis Area and Severity Index (PASI 75) and 
Investigator’s Global Assessment (IGA) 0/1 at week 12 as 
compared to placebo. Both trials achieved these coprimary 
endpoints, with a significantly greater proportion of patients 
at week 12 achieving PASI 75 on secukinumab (ERASURE: 
81.6%, FIXTURE: 77.1%) compared to placebo (ERASURE: 
4.5%, FIXTURE: 4.9%) or etanercept (FIXTURE: 44.0%), 
and a significantly greater proportion of patients achieving 
IGA 0/1 on secukinumab (ERASURE: 65.3%, FIXTURE: 
62.5%) compared to placebo (ERASURE: 2.4%, FIXTURE: 
Table 1 Summary of key Phase iii clinical trial results of secukinumab for the treatment of plaque psoriasis at week 12
Trial Year n Treatment (n) IGA 0/1a PASI 75 PASI 90 PASI 100
eRASURe13 2014 738 Secukinumab, 300 mg (245) 65.3% 81.6% 59.2% 28.6%
Secukinumab, 150 mg (245) 51.2% 71.6% 39.1% 12.8%
Placebo (248) 2.4% 4.5% 1.2% 0.8%
FiXTURe13 2014 1,306 Secukinumab, 300 mg (327) 62.5% 77.1% 54.2% 24.1%
Secukinumab, 150 mg (327) 51.1% 67.0% 41.9% 14.4%
etanercept (326) 27.2% 4.0% 20.7% 4.3%
Placebo (326) 2.8% 4.9% 1.5% 0.0%
CLeAR14 2015 676 Secukinumab, 300 mg (337) 80.8% 91.0% 72.8% 38.9%
Ustekinumab (339) 65.1% 79.1% 53.4% 25.7%
SCULPTURe16 2015 966 Secukinumab, 300 mg (484) – 90.1% – –
Secukinumab, 150 mg (482) – 84.4% – –
FeATURe18 2014 177 Secukinumab, 300 mg (59) 69.0% 75.9% 60.3% 43.1%
Secukinumab, 150 mg (59) 52.5% 69.5% 45.8% 8.5%
Placebo (59) 0.0% 0.0% 0.0% 0.0%
JUNCTURe19 2014 182 Secukinumab, 300 mg (60) 73.3% 86.7% 55.0% 26.7%
Secukinumab, 150 mg (61) 53.3% 71.7% 40.0% 16.7%
Placebo (61) 0.0% 3.3% 0.0% 0.0%
Notes: awith ≥2-grade improvement from baseline; PASi 100, 100% improvement in PASi from baseline; PASi 75, ≥75% improvement in PASi from baseline; PASi 90, ≥90% 
improvement in PASi from baseline.
Abbreviations: iGA, investigator’s Global Assessment; PASi, Psoriasis Area and Severity index.




Secukinumab in the treatment of psoriasis
2.8%) or etanercept (27.2%). Additionally, secukinumab 
demonstrated significantly improved PASI 90 (ERASURE: 
59.2%, FIXTURE: 20.7%) and PASI 100 (ERASURE: 
28.6%, FIXTURE: 24.1%) responses at week 12 as compared 
to placebo (PASI 90: 1.2%, 1.5%; PASI 100: 1.2%, 0.0%) 
and etanercept (PASI 90: 20.7%; PASI 100: 4.3%).
In the randomized, double-blind, controlled Phase III trial 
CLEAR, the clinical efficacy of secukinumab for psoriasis 
was evaluated head-to-head against ustekinumab.14 The pri-
mary endpoint for this study was the proportion of patients 
treated with secukinumab achieving PASI 90 at week 16 
as compared to ustekinumab. This study met the primary 
endpoint, with secukinumab demonstrating a superior PASI 
90 response at week 16 compared to ustekinumab (79.0% vs 
57.6%). Patients’ clinical responses to secukinumab at 
12 weeks were notably higher than the clinical responses 
observed at the same time point in ERASURE and FIX-
TURE, with 91.0% achieving PASI 75, 72.8% achieving 
PASI 90, and 38.9% achieving PASI 100 (Table 1). The 
clinical response to secukinumab was sustained at week 52, 
with superior efficacy as compared to ustekinumab noted in 
PASI 75 (92.5% vs 79.5%), PASI 90 (76.2% vs 60.6%), and 
PASI 100 (45.9% vs 36.7%).15
Another randomized, double-blind controlled Phase 
III trial was conducted to assess the optimal dosing for 
secukinumab in plaque psoriasis. In this study, SCULPTURE, 
secukinumab retreatment-as-needed was compared to a fixed-
interval regimen.16 Patients achieving PASI 75 response at 
week 12 were randomized 1:1 to fixed-interval dosing of 
secukinumab every 4 weeks or retreatment-as-needed every 
4 weeks upon loss of PASI 75 response plus loss of more than 
20% maximal PASI improvement. The primary endpoint for 
this study was non-inferiority of retreatment-as-needed com-
pared to fixed-interval dosing for maintaining PASI 75, but 
this primary endpoint was not achieved, as significantly more 
patients on fixed-interval maintained PASI 75 compared to 
retreatment-as-needed (78.2% vs 67.7%). On 5-year follow-up 
of the SCULPTURE study, patients demonstrated sustained 
responses to secukinumab, with 79.2% achieving PASI 75, 
59.5% achieving PASI 90, and 37.5% achieving PASI 100.17
The clinical efficacy of secukinumab for psoriasis was 
evaluated with secondary endpoints assessing the usability 
and tolerability of a prefilled syringe in FEATURE, a ran-
domized, double-blind, placebo-controlled Phase III trial.18 
The coprimary endpoints for this study were the proportions 
of patients achieving PASI 75 and IGA 0/1 at week 12 as 
compared to placebo. These coprimary endpoints were met, 
with significantly more patients treated with secukinumab 
achieving PASI 75 (75.9% vs 0%) and IGA 0/1 (69.0% vs 
0%) response as compared to placebo. Additionally, 60.3% 
and 43.1% of patients treated with secukinumab achieved 
PASI 90 and PASI 100 at 12 weeks, respectively.
The clinical efficacy of secukinumab for psoriasis was 
evaluated with secondary endpoints assessing the usability 
and tolerability of an auto-injector pen in JUNCTURE, 
another randomized, double-blind, placebo-controlled Phase 
III trial.19 The coprimary endpoints for this study were the 
proportions of patients achieving PASI 75 and IGA 0/1 at 
week 12 as compared to placebo. These coprimary endpoints 
were achieved, with significantly more patients treated with 
secukinumab achieving PASI 75 (86.7% vs 3.3%) and 
IGA 0/1 (73.3% vs 0%). Additionally, 55.0% and 26.7% 
of patients achieved PASI 90 and PASI 100 at 12 weeks, 
respectively. Patients demonstrated sustained responses to 
secukinumab at week 52, with 81.4% achieving PASI 75, 
64.1% achieving PASI 90, and 38.8% achieving PASI 100.19
In its Phase III trials, secukinumab has demonstrated 
efficacy for plaque psoriasis similar to other IL-17 inhibi-
tors (Table 2). Notably, it has shown superiority over both 
etanercept and ustekinumab in head-to-head comparisons. 
Secukinumab offers a highly efficacious treatment option 
for patients with moderate-to-severe psoriasis, and may be 
a preferred treatment option for patients who have disease 
recalcitrant to treatment with TNF-α inhibitors or IL-12/23 
inhibitors.
Efficacy in difficult-to-treat areas of 
psoriasis
Secukinumab has also demonstrated efficacy for psoriasis 
located in difficult-to-treat areas, including the scalp, palms 
and soles, and the nails.20,21 In a randomized, double-blind, 
placebo-controlled Phase III trial of patients with scalp 
psoriasis, treatment with 300 mg secukinumab for 12 weeks 
improved scalp disease severity as compared to placebo 
with respect to ≥90% reduction in Psoriasis Scalp Severity 
Index (52.9% vs 2.0%) and scalp only IGA 0/1 (56.9% vs 
5.9%).22 In the randomized, double-blind, placebo-controlled 
GESTURE study of patients with non-pustular palmoplan-
tar psoriasis, treatment with 300 mg secukinumab for 16 
weeks resulted in significant improvements in palmoplantar 
psoriasis disease severity, as measured by Palmoplantar 
Investigator’s Global Assessment 0/1 (33.2% vs 1.5%).23 In 
the randomized, double-blind, placebo-controlled Phase III 
trial of patients with nail psoriasis, TRANSFIGURE, treat-
ment with 300 mg secukinumab for 16 weeks significantly 
decreased Nail Psoriasis Severity Index as compared to 





placebo (−45.4% vs –11.2%).24 Additionally, in a single-
arm, open-label Phase III trial of patients with generalized 
pustular psoriasis, treatment with 150 mg secukinumab with 
up-titration to 300 mg as needed, resulted in treatment success 
in 83.3% of patients as measured by Clinical Global Impres-
sion.25 Secukinumab may benefit patients with isolated scalp, 
palmoplantar, or nail psoriasis.
Efficacy in psoriatic arthritis
Two pivotal randomized, double-blind, placebo-controlled 
Phase III trials evaluated the efficacy of 150 mg secukinumab 
in patients with active psoriatic arthritis, FUTURE-1 and 
FUTURE-2.26,27 The primary endpoint for both studies was 
the proportion of patients achieving ≥20% improvement 
in American College of Rheumatology score 20 (ACR20) 
at week 24 as compared to placebo. Both trials achieved 
this primary endpoint, with a significantly greater propor-
tion of patients at week 24 achieving ACR20 compared to 
 placebo (FUTURE-1: 50.0% vs 17.3%, FUTURE-2: 51.0% 
vs 15.3%) (Table 3). Patients also achieved better ACR50 
response (FUTURE-1: 34.7% vs 7.4%, FUTURE-2: 35.0% 
vs 18.2%) and slight reductions in joint structural damage 
as measured by Sharp score, as compared to placebo. These 
improvements were sustained through 52 weeks, with 59.9% 
of patients treated with secukinumab reporting ACR20 
response.28 In the FUTURE-1 cohort, 84.3% of patients 
demonstrated no radiographic progression of joint damage 
at 2 years.29
The clinical efficacy of secukinumab for psoriatic arthritis 
was evaluated with secondary endpoints assessing the usabil-
ity and tolerability of an auto-injector pen in FUTURE-3, 
a randomized, double-blind, placebo-controlled Phase III 
trial.30 The primary endpoint for this study was the proportion 
of patients achieving ACR20 at week 24 as compared to pla-
cebo. This primary endpoint was achieved, with significantly 
more patients treated with 150 mg secukinumab achieving 
ACR20 (42.0% vs 16.1%). Additionally, 18.8% of patients 
achieved ACR50 at 24 weeks.
Table 2 Clinical efficacy of biologic treatments for plaque psoriasis in pivotal Phase III trials
Drug/Trial Dose Frequency Contraindications PASI 75a PASI 90a PASI 100a
IL-23 inhibitors
Ustekinumab 45 mg 12 weeks None
PHOeNiX 1 67% 42% 13%
PHOeNiX 2 67% 42% 18%
ACCePT 68% 36% 16%
Guselkumab 100 mg 8 weeks None
vOYAGe i 91% 73% 37%
vOYAGe ii 86% 70% 34%
Tildrakizumab 100 mg 12 weeks None
ReSURFACe i 64% 35% 14%
ReSURFACe 2 61% 39% 12%
Risankizumabb 150 mg 12 weeks None
ultiMMa-1 – 75% 36%
ultiMMa-2 – 75% 51%
iMMvent – 72% 40%
iMMhance 89% 73% 47%
IL-17 inhibitors
Brodalumab 210 mg 2 weeks Crohn’s disease
AMAGiNe-1 83% 70% 42%
AMAGiNe-2 86% – 44%
AMAGiNe-3 85% – 37%
Secukinumab 300 mg 4 weeks Hypersensitivity to 
drugeRASURe 82% 59% 29%
FiXTURe 77% 54% 24%
ixekizumab 80 mg 4 weeks Hypersensitivity to 
drugUNCOveR-1 83% 65% 34%
UNCOveR-2 78% 60% 31%
UNCOveR-3 84% 65% 35%
Notes: Adapted from Yang et al (2018).46 aMeasured at 12 weeks, except guselkumab and risankizumab which were measured at 16 weeks. bNot currently approved for 
the treatment of plaque psoriasis. PASi 100, ≥100% improvement in PASi from baseline; PASi 75, ≥75% improvement in PASi from baseline; PASi 90, ≥90% improvement in 
PASi from baseline.
Abbreviation: PASi, Psoriasis Area and Severity index.
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The efficacy of secukinumab for treating the clinical signs 
and symptoms of psoriatic arthritis, as well as radiographic 
progression, was evaluated in the randomized, double-blind, 
placebo-controlled Phase III trial FUTURE-5.31 The primary 
endpoint for this study was the proportion of patients achiev-
ing ACR20 response at week 16 as compared to placebo, with 
secondary endpoints assessing changes in the radiographic 
progression of the disease. This primary endpoint was 
achieved, with significantly more patients treated with 150 mg 
secukinumab achieving ACR20 (57.5% vs 27.4%). Addition-
ally, 33.9% and 16.5% of patients on 150 mg secukinumab 
achieved ACR50 and ACR70, respectively. In this study, 
radiographic progression was significantly inhibited at week 
24 as compared to placebo.
Safety
In pooled analyses of Phase II and III trials, secukinumab 
was found to be well-tolerated.32,33 Currently published 
clinical trials have demonstrated a favorable safety profile 
for secukinumab for up to 5 years of treatment.17,32 No cases 
of reactivation of latent tuberculosis have been reported with 
secukinumab treatment in its clinical trials.33 Secukinumab 
treatment has not been associated with any increased risk 
of anxiety or depression. Neutropenia was observed rarely 
during clinical trials of secukinumab, but most cases were 
transient and reversible, without association with serious 
infection.12,33
Table 3 Summary of key Phase iii clinical trial results of secukinumab for the treatment of psoriatic arthritis




Change in  
SF-36 PCS
FUTURe-126 2015 606 Secukinumab, 150 mg (202) 50.0% 34.7%
−0.40 –1.62 5.91
Secukinumab, 75 mg (202 50.5% 30.7%
−0.41 –1.67 5.41
Placebo (202) 17.3% 7.4%
−0.17 –0.77 1.82
FUTURe-227 2015 397 Secukinumab, 300 mg (100) 54.0% 35.0% –0.56 –1.61 7.25
Secukinumab, 150 mg (100) 51.0% 35.0% –0.48 –1.58 6.39
Secukinumab, 75 mg (99) 29.3% 18.2% –0.32 –1.12 4.38
Placebo (98) 15.3% 7.1% –0.31 –0.96 1.95
FUTURe-330 2018 416 Secukinumab, 300 mg (139) 48.2% 34.5% –0.38 –1.56 6.46
Secukinumab, 150 mg (138) 42.0% 18.8% –0.27 –1.24 3.42
Placebo (137) 16.1% 8.8% –0.17 –0.64 2.94
FUTURe-531 2018 996 Secukinumab, 300 mg (222) 62.6% 39.6% –0.55 –1.49 –
Secukinumab, 150 mg with 
loading dose (220)
55.5% 35.9% –0.44 –1.29 –
Secukinumab 150 mg without 
loading dose (222)
59.5% 32.0% –0.45 –1.29 –
Placebo (332) 27.4% 8.1% –0.21 –0.63 –
Notes: endpoints for all trials were measured at week 24, except for FUTURe-5 which were measured at week 16. ACR20, ≥20% improvement in ACR from baseline; 
ACR50, ≥50% improvement in ACR from baseline.
Abbreviations: ACR, American College of Rheumatology score; DAS-CRP, 28-joint Disease Activity Score on the basis of levels of C-reactive protein; HAQ-Di, Health 
Assessment Questionnaire-Disability index; SF-36 PCS, Short Form 36-item Physical Component Summary Score of the Medical Outcomes Survey.
Common adverse effects of secukinumab treatment 
include headache and nasopharyngitis. Patients treated with 
secukinumab have been shown, in Phase II and III trials, to 
have an increased risk of mucocutaneous candidiasis, which 
can be successfully treated with oral or topical therapies and 
typically does not require discontinuation of secukinumab 
therapy.32,33 Although secukinumab has not been shown 
to increase the risk of IBD flares, secukinumab should be 
avoided in patients with IBD.12
The safety profile of secukinumab is comparable to that 
of other IL-17 inhibitors, and continues to be well-tolerated 
for up to 5 years of treatment. In patients for whom the drug 
is not contraindicated, secukinumab is only associated with 
mild side effects that rarely lead to cessation of therapy. 
However, TNF-α inhibitors and ustekinumab have more 
safety data spanning far longer treatment durations, and 
may thus be a more optimal treatment option for patients 




Many biologics are available for the treatment of plaque 
psoriasis, but these therapies have varying efficacy and safety 
profiles (Table 1). In general, IL-17 and IL-23 inhibitors 
demonstrate higher efficacy than older TNF-α inhibitors, 
while sub-analyses of the onset of action of biologic therapies 





demonstrated that IL-17 inhibitors act more quickly than 
ustekinumab and TNF-α inhibitors.34 Of note, secukinumab 
resulted in PASI 75 response in 25% of patients in 3.0 weeks, 
and achieved an average of 50% reduction in PASI score in 
3.0 weeks. Brodalumab (Siliq, Valeant Pharmaceuticals, 
Bridgewater, NJ, USA) had the most rapid onset of action 
among any biologic therapy in this analysis, with 25% of 
patients achieving PASI 75 at 2.1 weeks, and achieving an 
average of 50% reduction in PASI score at 1.8 weeks.
These data demonstrate that IL-17 inhibitors are ideal for 
psoriasis patients who require rapid clearance of their skin. 
Although a chronic disease, certain patients may benefit from 
more rapid response than others, such as patients with sig-
nificantly impaired quality of life. Discouraged patients with 
recalcitrant disease may lose confidence about treatment if 
they do not observe efficient improvement of their skin symp-
toms, which can lead to poor medication adherence.35 Thus, 
it is important to treat these patients early with rapid-acting 
biologic therapies, a niche that IL-17 inhibitors fill well.
Currently-approved IL-17 inhibitors – secukinumab, 
brodalumab, and ixekizumab – all achieve an average of 
50% reduction in PASI within 2 weeks.34 However, the most 
rapidly-acting IL-17 inhibitor, brodalumab, has a black box 
warning for depression. Although the actual risk for suicidal-
ity and depression with brodalumab is uncertain,36 this pos-
sible risk must be discussed with patients prior to prescribing 
brodalumab. Secukinumab has no black box warnings that 
need to be discussed prior to initiating treatment, and no 
increased risk of depression or suicidality, as observed in its 
Phase III clinical trials. Thus, patients concerned about the 
side effect profiles of biologics are sometimes more amenable 
to starting on secukinumab, rather than brodalumab or TNF-α 
inhibitors, which have multiple black box warnings.
Convenience
Patient convenience should also be considered when select-
ing a biologic medication for psoriasis patients. IL-23 and 
IL-12/23 inhibitors are dosed more infrequently than IL-17 
inhibitors (Table 2), and may be preferable for patients who 
require supervision for medication administration by a health 
care professional or who have issues with medication compli-
ance. However, secukinumab is still dosed more infrequently 
than some TNF-α inhibitors that are dosed every 1–2 weeks.
The JUNCTURE and FEATURE Phase III trials demon-
strated that secukinumab administered by autoinjector pen or 
prefilled syringe continues to be well-tolerated at 1 year under 
the currently-approved dosing regimen.19,37 No increased 
risk of injection-site reactions has been reported with 
secukinumab treatment with either method of  administration. 
Patients who are able to comply with a regular monthly dos-
ing regimen may benefit from secukinumab treatment due to 
its convenience over older biologic therapies, as well as for 
other reasons outlined in this manuscript.
Treatment of comorbid disease
Up to 40% of psoriasis patients have or will develop psoriatic 
arthritis during their lifetimes, so treatment of joint symptoms 
in addition to skin symptoms is critical to prevent irreversible 
joint damage. Secukinumab is one of six biologics currently 
approved for the treatment of both psoriatic arthritis and 
psoriasis vulgaris, a group that also includes etanercept, 
adalimumab, infliximab, ustekinumab, and ixekizumab. 
Secukinumab results in excellent ACR response after 24 
weeks of treatment, but this biologic also inhibits radio-
graphic joint damage in psoriatic arthritis patients for up to 
2 years.29 Thus, secukinumab offers a long-term treatment 
option for psoriatic arthritis patients that does not just slow 
joint damage, but prevents further damage from occurring.
Almost half of psoriasis patients without psoriatic arthri-
tis harbor subclinical joint inflammation, thought to be an 
antecedent to inflammatory arthritis.38 Of these psoriasis 
patients with subclinical synovitis and arthralgia symptoms at 
baseline, 55% developed psoriatic arthritis according to Clas-
sification of Psoriatic Arthritis criteria within 1 year. Early 
intervention is of paramount importance for arthritis patients, 
as joint damage is permanent.39 Thus, secukinumab treatment 
in patients with nonspecific joint pain may be of benefit, due 
to the high risk of progression to joint involvement.
Cost-effectiveness
Biologics’ cost is a primary concern for dermatologists when 
selecting treatment for moderate-to-severe psoriasis patients.40 
Current estimates of the annual cost of achieving PASI 75 
response with secukinumab range from $75,671 to $105,131 
(US$).41,42 Previous analyses from Europe have shown 
secukinumab to be more cost-effective than TNF-α inhibitors 
as a first-line agent due to its superior clinical efficacy, ulti-
mately resulting in cost savings.43 However, cost estimates for 
all biologics vary widely in the literature, and are accompanied 
by high levels of uncertainty.44,45 Further research is needed to 
evaluate the cost-effectiveness of all biologics for psoriasis.
Conclusion
Dermatologists have a plethora of options available for the 
treatment of patients with moderate-to-severe psoriasis, but 
the decision of which medication to choose is often difficult. 
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Secukinumab is a highly-efficacious, fast-acting biologic 
therapy with a relatively favorable safety profile that can 
be considered in patients requiring rapid clearance of their 
psoriasis and patients with psoriasis in difficult-to-treat 
areas, such as the scalp, palms and soles, or nails. Addition-
ally, secukinumab is a preferred treatment for patients with 
comorbid psoriatic arthritis or arthralgia symptoms, due to 
its ability to inhibit progression of arthritic disease. Careful 
consideration of clinical efficacy, safety, cost, convenience, 
onset of action, and management of comorbid disease is 
necessary when selecting treatment for individual patients.
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